Vertex Pharmaceuticals Inc (VRTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $136.56B
Last updated: Nov 17, 2026 at 11:05 AM ET
Vertex Pharmaceuticals Inc (VRTX) P/E Ratio & Valuation History
Vertex Pharmaceuticals (VRTX) trades at 30.0x trailing earnings and 10.5x sales. Its P/E of 30.0x is above its 5-year median of 23.7x. Its forward P/E is 26.2x. The median P/E across 5 similar companies is 33.5x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 14.5% higher over the next year. Its free cash flow yield is 2.3%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 30.0x |
| Forward P/E | 26.2x |
| Price to sales | 10.5x |
| Price to book | 6.5x |
| EV/EBITDA | 29.8x |
| Price to FCF | 42.6x |
| EV/FCF | 42.4x |
| PEG | 2.3 |
| FCF yield | 2.3% |
Historical Medians
Against its 10-year medians, its P/E is 11.1% above 27.0x, its P/S is 3.7% below 10.9x and its P/B is 4.4% below 6.8x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 30.0x | 23.7x | 27.0x |
| P/S | 10.5x | 9.5x | 10.9x |
| P/B | 6.5x | 6.2x | 6.8x |
Valuation History
Over the 9 of the 10 year ends shown that have a P/E, its P/E ranged from 16.9x in 2021 to 87.7x in 2016.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $453.36 | 24.6x | 9.7x | 6.2x |
| 2024 | $402.70 | N/A | 9.5x | 6.4x |
| 2023 | $406.89 | 26.7x | 10.7x | 6.0x |
| 2022 | $288.78 | 19.4x | 8.3x | 5.4x |
| 2021 | $219.60 | 16.9x | 7.5x | 5.6x |
| 2020 | $236.34 | 22.9x | 9.9x | 7.2x |
| 2019 | $218.95 | 41.1x | 13.6x | 9.4x |
| 2018 | $165.71 | 40.5x | 13.8x | N/A |
| 2017 | $149.86 | 52.4x | 15.1x | 18.8x |
| 2016 | $73.67 | 87.7x | 10.6x | 13.6x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About VRTX
What is VRTX's forward P/E ratio?
Vertex Pharmaceuticals has a forward P/E ratio of 26.2x.
Is VRTX stock overvalued?
GNG's valuation label for VRTX is Fairly valued. Its P/E of 30.0x compares with a median of 33.5x across 5 similar companies.
What is VRTX's price to sales ratio?
Vertex Pharmaceuticals has a price to sales ratio of 10.5x.
What is Vertex Pharmaceuticals's average P/E ratio over 5 years?
Vertex Pharmaceuticals's median P/E over the last 5 years is 23.7x, from 51 month-end values through Oct 2026.
What is VRTX's PEG ratio?
Vertex Pharmaceuticals has a PEG ratio of 2.3.
VRTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors